**Novo Nordisk Shares Plunge After Ozempic Alzheimer’s Trial Failure**
Shares of Novo Nordisk, the Danish pharmaceutical giant, experienced a significant drop of 12.4% on November 24, marking the steepest decline since July 2021. This downturn followed the disappointing news that the company’s widely-used weight-loss medication, Ozempic, failed in clinical trials aimed at treating Alzheimer’s disease. The company announced the discontinuation of a planned one-year extension for two studies assessing the drug’s potential to slow the progression of Alzheimer’s.
The trials, which involved 3,500 participants diagnosed with mild Alzheimer’s, were deemed likely to fail, with Morgan Stanley analysts estimating a 75% probability of unsuccessful outcomes prior to the announcement. Jared Holz, a health strategist at Mizuho, noted that the stock’s decline was exacerbated by Novo’s inability to provide any positive insights from the trials, stating, “There was talk that the trial could fail in totality but still illustrate differentiation in certain patient populations.”
This setback is particularly significant for Novo Nordisk, which had high hopes for a revival under new CEO Mike Doustdar, especially with the ambitious goal of addressing Alzheimer’s disease. The company has also lost its leading position in the obesity and weight-loss market to Eli Lilly, a US-based competitor, and has struggled to reclaim that status.
In the wake of Novo’s announcement, Eli Lilly’s stock also saw a decline in pre-market trading, while Biogen Inc., which is developing alternative Alzheimer’s treatments, experienced a 6.7% increase.
On November 24, Novo Nordisk revealed that cognitive assessments from the Ozempic study indicated no slowing of Alzheimer’s progression among participants. Per Hansen, an investment economist at Nordnet AB, described the trials as a “lottery ticket,” while Evan Seigermann, an analyst at BMO Capital Markets, emphasized that even a slim chance of success could have been transformative.
Ozempic, which mimics the gut hormone GLP-1, has already demonstrated effectiveness in various obesity-related health issues, including heart attack and stroke prevention. Analysts suggest that while Ozempic may not treat Alzheimer’s, it could have had potential in preventing the disease. Ivan Koychev, an associate professor in neuropsychiatry at Imperial College London, noted that in advanced Alzheimer’s cases, preventing further decline may not be sufficient to restore damaged neural networks.
Despite the challenges, the market for Alzheimer’s drug development remains lucrative, with ongoing interest from pharmaceutical companies.
**FAQ**
**Q: What happened to Novo Nordisk’s stock on November 24?**
A: Novo Nordisk’s stock plummeted by 12.4% after the company announced that its weight-loss drug Ozempic failed in trials for treating Alzheimer’s disease.
